CORONA, Calif., Aug. 8 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, today reported financial results for its second quarter ended June
30, 2006.
Net revenue for the second quarter increased 23 percent to $510.4
million, compared to $416.3 million for the second quarter ended June 30,
2005. Second quarter total net revenue growth was driven by higher product
sales in the Company's Generic division as a result of new products
launched since the second quarter of 2005.
The Company recorded a net loss for the second quarter of $15.6
million, or $0.15 per basic and diluted share, compared to net income of
$40.4 million, or $0.35 per diluted share, for the same period of 2005. The
net loss for the second quarter included a $67.0 million non-cash asset
impairment charge ($41.6 million, net of tax) related primarily to
Actigall(R) and Alora(R) product rights, and $6.7 million ($4.2 million,
net of tax) of facility rationalization costs. Excluding these charges,
adjusted net income and earnings per share for the second quarter of 2006
were $30.2 million and $0.27 respectively. A table reconciling reported net
income and earnings per share to adjusted net income and earnings per share
is provided below.
Cash flow from operations for the second quarter was $60.5 million. For
the first six months of 2006, cash flow from operations increased 10
percent to $196.2 million, compared to $178.9 million in the prior year
period. Cash and marketable securities were $769.4 million as of June 30,
2006.
"We are pleased with the progress made over the last several months as
we continue to implement our strategic initiatives aimed at expanding our
pipeline and lowering our cost structure," began Allen Chao, Ph.D.,
Watson's Chairman and Chief Executive Officer. "Our generic product
pipeline has 49 ANDAs on file with the FDA and we continue to make progress
towards the introduction of several new generic products later in the year.
Assuming we launch these new products, we remain on track to achieve the
operating targets we provided in May 2006."
"Activities surrounding the closure and divesture of our Puerto Rico
and Phoenix facilities are well underway, with completion of these
important projects anticipated by early 2007. Additionally, we are pleased
to report that the expansion of our operations in India is on track, with
senior management in place for all critical functions."
"With respect to the Andrx acquisition, integration planning is
underway and we look forward to closing the transaction," Dr. Chao said.
For the six months ended June 30, 2006, total net revenue increased 12
percent to $917.6 million, as compared to $817.1 million for the first six
months of 2005. Net income for the first six months of 2006 was $9.6
million, or $0.09 per basic and diluted share, as compared to net income of
$79.1 million, or $0.67 per diluted share, for the same period of 2005.
Second Quarter 2006 Results
Net Revenues
Three Months Ended June 30,
($ in millions): 2006 2005 Change
Generic products
Generics $340.8 $234.5 45%
Generic oral contraceptives 78.6 78.0 1%
Total generic product sales 419.4 312.5 34%
% of product net sales 83% 76%
Brand products
Specialty Products 44.5 54.7 (19)%
Nephrology 43.6 46.0 (5)%
Total brand product sales 88.1 100.7 (13)%
% of product net sales 17% 24%
Total product net sales 507.5 413.2 23%
Other 2.9 3.1 (7)%
Total net revenues $510.4 $416.3 23%
Six Months Ended June 30,
2006 2005 Change
Generic products
Generics $586.3 $446.0 31%
Generic oral contraceptives 154.6 159.6 (3)%
Total generic product sales 740.9 605.6 22%
% of product net sales 81% 75%
Brand products
Specialty Products 83.5 118.2 (29)%
Nephrology 87.8 87.1 1%
Total brand products 171.3 205.3 (17)%
% of product net sales 19% 25%
Total product net sales 912.2 810.9 12%
Other 5.4 6.2 (12)%
Total net revenues $917.6 $817.1 12%
Generic product sales for the second quarter increased $107.0 million
or 34 percent to $419.4 million, compared to $312.5 million in the prior
year period, primarily due to the Company's launch of pravastatin sodium
tablets during the quarter and the addition of oxycodone HCl
controlled-release tablets C-II in the fourth quarter 2005. Pravastatin
sodium tablets are the authorized generic version of Bristol-Myers Squibb's
Pravachol(R) product. On a sequential quarter basis, generic product sales
increased $98.0 million or 30 percent from the first quarter 2006, largely
due to the launch of pravastatin sodium.
"Our base generic business remains solid and we have seen relatively
stable pricing in the marketplace since the first quarter," continued Dr.
Chao. "Excluding the launch of pravastatin sodium, our generic business
grew in both sales and gross profit compared to the first quarter, despite
higher facility rationalization costs."
Brand product sales for the second quarter decreased $12.6 million or
13 percent to $88.1 million, compared to $100.7 million in the second
quarter of 2005, due primarily to a decline in sales of Specialty Products.
On a sequential quarter basis, brand product sales increased six percent
from the first quarter 2006.
Gross Margin
Three Months Ended
June 30,
2006 2005
Overall consolidated gross margin 35.2% 49.3%
Generic product sales 26.9% 39.8%
Brand product sales 72.4% 77.1%
Gross margin on product net sales 34.8% 48.9%
Gross profit was $179.5 million in the second quarter of 2006, compared
to $205.1 million for the second quarter of 2005 and $172.5 million in the
first quarter 2006. The decrease in gross profit compared to the prior year
period was due primarily to lower brand product sales and lower generic
product pricing from the year ago period. The increase in gross profit over
the first quarter 2006 was due to increased generic product sales,
partially offset by higher facility rationalization costs.
Overall gross margin was 35.2 percent in the second quarter of 2006
compared to 49.3 percent in the second quarter of 2005 and 42.4 percent in
the first quarter 2006, due to a decrease in both generic and brand product
gross margins. The decrease in generic product gross margin compared to the
prior year period was due primarily to the addition of pravastatin sodium
tablets and oxycodone HCl controlled-release tablets, both distributed
generic products with lower gross margins. Additionally, facility
rationalization costs contributed to the decline in generic product gross
margins. The decrease in brand product gross margin was due primarily to
higher brand product manufacturing costs.
Research and development investment decreased slightly to $31.1 million
in the second quarter of 2006 compared to $31.5 million in the same period
of 2005.
Selling, general and administrative expenses for the second quarter of
2006 increased $2.6 million, or four percent, to $70.8 million, compared to
$68.1 million in the second quarter of 2005.
Generic Research and Development
During the second quarter 2006, Watson submitted 10 new Abbreviated New
Drug Applications (ANDAs) with the Food and Drug Administration (FDA). The
Company's generic pipeline currently has 49 Abbreviated New Drug
Applications (ANDAs) on file with the FDA. Included in the 49 ANDAs on file
are 12 products that have received tentative approval and nine products
that are potential first-to-file or shared exclusivity opportunities.
Brand Research and Development
In Watson's brand product pipeline, the Company has initiated Phase III
studies on its gel formulation of oxybutynin for overactive bladder.
Additionally, the Company remains on target to complete the efficacy
portion of its Phase III studies for silodosin, a product under development
for benign prostatic hyperplasia, in the third quarter 2006, followed by a
one year open label study.
2006 Financial Outlook
Watson's forecasts are based on the Company's actual results for the
first half of 2006, management's current belief about prescription and
pricing trends, customer inventory levels and the anticipated timing of
future product launches. The current forecast excludes the potential
effects of the Company's pending transaction to acquire all outstanding
shares of common stock of Andrx Corporation.
Watson's previously forecasted total net revenue estimate for the full
year of 2006 remains unchanged at between $1.8 billion and $1.9 billion.
The Company's forecast for 2006 Generic revenue is estimated at $1.4
billion to $1.5 billion and assumes the launches of generic versions of
Flonase(R), Duragesic(R) and Seasonale(R) during the later half of 2006.
The Company's forecast for 2006 Brand revenue is between $350 million and
$360 million. GAAP earnings per diluted share for 2006 is expected to be
between $0.89 and $0.97. The full year earnings per diluted share forecast
includes $41.6 million, net of tax, in expense related to the asset
impairment charge. Annual weighted average diluted shares outstanding are
forecast to be 116.5 million shares. Cash flow from operations for the full
year of 2006 is expected to be between $325 million and $340 million.
Webcast and Conference Call Details
Watson will host a conference call and webcast today at 5:00 p.m.
Eastern Daylight Time to discuss 2006 second quarter results, projections
for the remainder of 2006 and recent corporate developments. The dial-in
number to access the call is (877) 251-7980, or from international
locations, (706) 643-1573. A taped replay of the call will be available by
calling (800) 642-1687 with access pass code 2907472. The replay may be
accessed from international locations by dialing (706) 645-9291 and using
the same pass code. This replay will remain in effect until midnight
Eastern Daylight Time, Friday, August 11, 2006. To access the live webcast,
go to Watson's Investor Relations Web site at http://ir.watsonpharm.com.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a
leading specialty pharmaceutical company that develops, manufactures,
markets, sells and distributes brand and generic pharmaceutical products.
Watson pursues a growth strategy combining internal product development,
strategic alliances and collaborations and synergistic acquisitions of
products and businesses.
For press release and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watsonpharm.com.
Forward-Looking Statement
Statements contained in this press release that refer to Watson's
estimated or anticipated future results or other non-historical facts are
forward-looking statements that reflect Watson's current perspective of
existing trends and information as of the date of this release. For
instance, any statements in this press release concerning prospects related
to Watson's strategic initiatives, product introductions and anticipated
financial performance are forward-looking statements. It is important to
note that Watson's goals and expectations are not predictions of actual
performance. Watson's performance, at times, will differ from its goals and
expectations. Actual results may differ materially from Watson's current
expectations depending upon a number of factors affecting Watson's
business. These factors include, among others, the inherent uncertainty
associated with financial projections; the impact of competitive products
and pricing; successful consummation and integration of strategic
transactions, including the Company's March 16, 2006 acquisition of
Sekhsaria Chemicals, Ltd. and its March 12, 2006 agreement to acquire all
outstanding shares of common stock of Andrx Corporation (subject to
obtaining the approval of antitrust authorities and other approvals
necessary to complete the Andrx merger); the ability to recognize the
anticipated synergies and benefits of strategic transactions; variability
of revenue mix between the Company's Brand and Generic business units;
periodic dependence on a small number of products for a material source of
net revenue or income; variability of trade buying patterns; changes in
generally accepted accounting principles; risks that the carrying values of
assets may be negatively impacted by future events and circumstances;
timely and successful consummation and implementation of strategic
initiatives; the timing and success of product launches; the difficulty of
predicting the timing or outcome of product development efforts and FDA or
other regulatory agency approvals or actions; the uncertainty associated
with the identification and successful consummation of external business
development transactions; market acceptance of and continued demand for
Watson's products; costs and efforts to defend or enforce intellectual
property rights; difficulties or delays in manufacturing; the availability
and pricing of third party sourced products and materials; successful
compliance with FDA and other governmental regulations applicable to
Watson's and its third party manufacturers' facilities, products and/or
business; uncertainties related to the timing and outcome of litigation and
other claims; changes in the laws and regulations, including Medicare and
Medicaid, affecting among other things, pricing and reimbursement of
pharmaceutical products; and such other risks and uncertainties detailed in
Watson's periodic public filings with the Securities and Exchange
Commission, including but not limited to Watson's Annual Report on Form
10-K for the year ended December 31, 2005 and Watson's Quarterly Report on
Form 10-Q for the period ended March 31, 2006. Except as expressly required
by law, Watson disclaims any intent or obligation to update these
forward-looking statements.
Flonase(R) is a registered trademark of Glaxo Group Limited,
Duragesic(R) is a registered trademark of Johnson & Johnson and
Seasonale(R) is a registered trademark of Duramed Pharmaceuticals, Inc.
The following table presents Watson's results of operations for the
three and six months ended June 30, 2006 and 2005:
Table 1
Watson Pharmaceuticals, Inc.
Condensed Consolidated Statements of (Loss) Income
(Unaudited; in thousands, except per share amounts)
Three Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
Restated Restated
Net revenues $510,356 $416,266 $917,589 $817,094
Cost of sales 330,860 211,213 565,614 418,163
Gross profit 179,496 205,053 351,975 398,931
Operating expenses:
Research and development 31,125 31,486 60,962 60,324
Selling, general and
administrative 70,774 68,125 137,524 131,776
Amortization 41,101 41,101 82,201 81,739
Loss on impairment 66,981 -- 66,981 --
Total operating expenses 209,981 140,712 347,668 273,839
Operating (loss) income (30,485) 64,341 4,307 125,092
Other income (expense):
Earnings (losses) on equity
method investments 1,646 (997) 1,454 (875)
Gain on sale of securities -- -- 3,695 --
(Loss) on early extinguishment
of debt 195 -- (525) --
Interest income 6,913 4,546 13,165 8,652
Interest expense (3,322) (3,624) (6,623) (6,914)
Other (expense) income (97) 185 8 (39)
Total other income, net 5,335 110 11,174 824
(Loss) income before income tax
provision (25,150) 64,451 15,481 125,916
(Benefit) provision for income
taxes (9,532) 24,002 5,867 46,854
Net (loss) income $(15,618) $40,449 $9,614 $79,062
Diluted (loss) earnings per share $(0.15) $0.35 $0.09 $0.67
Diluted weighted average shares
outstanding 101,666 121,253 102,125 122,671
The following table presents Watson's Condensed Consolidated Balance
Sheets as of June 30, 2006 and December 31, 2005:
Table 2
Watson Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands)
June 30, December 31,
2006 2005
Assets
Cash and cash equivalents $600,411 $467,451
Marketable securities 169,037 162,475
Accounts receivable, net 347,813 333,832
Inventories 310,421 278,062
Other current assets 144,375 118,610
Property and equipment, net 449,375 436,149
Investments and other assets 88,898 76,051
Product rights, net 600,662 751,808
Goodwill 479,945 455,595
Total assets $3,190,937 $3,080,033
Liabilities & Stockholders' Equity
Current liabilities $381,108 $245,670
Long-term debt 574,013 587,935
Deferred income taxes and other
liabilities 104,526 142,187
Stockholders' equity 2,131,290 2,104,241
Total liabilities & stockholders'
equity $3,190,937 $3,080,033
The following table presents Watson's Condensed Consolidated Statements
of Cash Flows for the six months ended June 30, 2006 and 2005:
Table 3
Watson Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited; in thousands)
Six Months Ended
June 30,
2006 2005
Restated
Cash Flows from Operating Activities:
Net income $9,614 $79,062
Reconciliation to net cash provided
by operating activities:
Depreciation and amortization 106,770 101,378
Loss on impairment 66,981 --
Deferred income tax provision (benefit) (61,857) (12,130)
Provision for inventory reserve 10,701 29,584
Restricted stock and stock option
compensation 6,653 --
Other adjustments to reconcile net
income to net cash provided (6,304) 1,254
Changes in assets and liabilities:
Accounts receivable, net (13,618) (19,799)
Inventories (38,542) 2,407
Accounts payable and accrued expense 84,425 (5,893)
Income taxes payable 35,106 (8,541)
Other changes to assets and liabilities (3,704) 11,622
Total adjustments 186,611 99,882
Net cash provided by operating
activities 196,225 178,944
Cash Flows from Investing Activities:
Additions to property, equipment and
product rights (18,481) (38,530)
Proceeds from sales of marketable
securities -- 220,083
Acquisition of Sekhsaria (29,664) --
Other (3,604) 1,000
Net cash (used in) provided by
investing activities (51,749) 182,553
Cash Flows from Financing Activities:
Redemption of senior unsecured notes (14,585) --
Repurchase of common stock -- (182,585)
Proceeds from stock plans and other 7,283 11,175
Other (4,214) (5)
Net cash used in financing activities (11,516) (171,415)
Net increase in cash and cash
equivalents 132,960 190,082
Cash and cash equivalents at beginning
of period 467,451 298,653
Cash and cash equivalents at end of period $600,411 $488,735
The following table presents a reconciliation of reported net income
and earnings per diluted share to adjusted net income and earnings per
share for the three months ended June 30, 2006:
Table 4
Watson Pharmaceuticals, Inc.
Reconciliation Table
Three months ended
June 30,
2006 2006 2005
GAAP Adjusted GAAP
Restated
Diluted (loss) earnings per share
calculation
Reported net (loss) income $(15,618) $(15,618) $40,449
Add: Asset impairment charge, net
of tax -- 41,595 --
Facility rationalization
costs, net of tax -- 4,186 --
Net (loss) income, GAAP and
adjusted (15,618) 30,163 40,449
Add: Interest expense on CODES,
net of tax -- 1,784 1,808
Net (loss) income, adjusted for
interest on CODES $(15,618) $31,947 $42,257
Basic weighted average common
shares outstanding 101,666 101,666 106,359
Effect of dilutive securities:
Conversion of CODES -- 14,357 14,357
Dilutive stock options -- 181 537
Diluted weighted average common
shares outstanding 101,666 116,204 121,253
Diluted (loss) earnings per share -
GAAP and adjusted $(0.15) $0.27 $0.35
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
SOURCE Watson Pharmaceuticals, Inc.
 back to top
Related links:
http://www.watsonpharm.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Patty Eisenhaur, Director, Investor Relations
of Watson Pharmaceuticals, Inc., +1-951-493-5611
|
